Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 474

1.

Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Zhou SF.

Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. Review.

PMID:
19817501
2.

Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Zhou SF.

Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000.

PMID:
19902987
3.

Applications of CYP450 testing in the clinical setting.

Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA.

Mol Diagn Ther. 2013 Jun;17(3):165-84. doi: 10.1007/s40291-013-0028-5. Review.

4.

The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.

de Leon J, Susce MT, Murray-Carmichael E.

Mol Diagn Ther. 2006;10(3):135-51. Review.

PMID:
16771600
5.

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.

Zanger UM, Raimundo S, Eichelbaum M.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37. Epub 2003 Nov 15. Review.

PMID:
14618296
6.

Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.

Fux R, Mörike K, Pröhmer AM, Delabar U, Schwab M, Schaeffeler E, Lorenz G, Gleiter CH, Eichelbaum M, Kivistö KT.

Clin Pharmacol Ther. 2005 Oct;78(4):378-87.

PMID:
16198657
7.

Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.

Lind AB, Reis M, Bengtsson F, Jonzier-Perey M, Powell Golay K, Ahlner J, Baumann P, Dahl ML.

Clin Pharmacokinet. 2009;48(1):63-70. doi: 10.2165/0003088-200948010-00005.

PMID:
19071885
8.

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.

Kirchheiner J, Heesch C, Bauer S, Meisel C, Seringer A, Goldammer M, Tzvetkov M, Meineke I, Roots I, Brockmöller J.

Clin Pharmacol Ther. 2004 Oct;76(4):302-12.

PMID:
15470329
9.

Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.

Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA.

Clin Pharmacol Ther. 2004 Dec;76(6):536-44.

PMID:
15592325
10.

Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.

Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lötsch J, Roots I, Brockmöller J.

Pharmacogenomics J. 2007 Aug;7(4):257-65. Epub 2006 Jul 4.

PMID:
16819548
11.

Complexities of CYP2D6 gene analysis and interpretation.

Gaedigk A.

Int Rev Psychiatry. 2013 Oct;25(5):534-53. doi: 10.3109/09540261.2013.825581. Review.

PMID:
24151800
12.

The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.

Lefebvre J, Poirier L, Poirier P, Turgeon J, Lacourciere Y.

Br J Clin Pharmacol. 2007 May;63(5):575-82. Epub 2006 Nov 10.

13.
15.

CYP2D6 genotype affects age-related decline in flecainide clearance: a population pharmacokinetic analysis.

Doki K, Homma M, Kuga K, Aonuma K, Kohda Y.

Pharmacogenet Genomics. 2012 Nov;22(11):777-83. doi: 10.1097/FPC.0b013e3283588fe5.

PMID:
22941032
16.

Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.

Neafsey P, Ginsberg G, Hattis D, Sonawane B.

J Toxicol Environ Health B Crit Rev. 2009;12(5-6):334-61. doi: 10.1080/10937400903158342. Review.

PMID:
20183526
17.

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.

Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Mörike K, Stüven T, Eichelbaum M.

Pharmacogenetics. 1998 Feb;8(1):15-26.

PMID:
9511177
18.

Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.

Nichols AI, Lobello K, Guico-Pabia CJ, Paul J, Preskorn SH.

J Clin Psychopharmacol. 2009 Aug;29(4):383-6. doi: 10.1097/JCP.0b013e3181acc4dd.

PMID:
19593180
19.

Correlation of genotype, phenotype, and mRNA expression of CYP2D6 and CYP2C19 in peripheral blood leukocytes (PBLs).

Kuhlmann JB, Wensing G, Kuhlmann J.

Int J Clin Pharmacol Ther. 2014 Feb;52(2):143-50. doi: 10.5414/CP201966.

PMID:
24361088
20.

Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups.

Luo HR, Aloumanis V, Lin KM, Gurwitz D, Wan YJ.

Am J Pharmacogenomics. 2004;4(6):395-401.

PMID:
15651900

Supplemental Content

Support Center